logo
  

Syntel Q3 Profit Beats Estimates; Lifts FY14 Earnings Outlook - Quick Facts

Syntel Inc. (SYNT), an IT services provider, Thursday, reported net income for the third-quarter of $61.6 million or $1.47 per share, up from $59.4 million or $1.42 per share in the prior-year period. On average, 13 analysts polled by Thomson Reuters expected earnings per share of $1.39 for the quarter. Analysts' estimates typically exclude one-time items.

Quarterly revenue rose 9 percent to $228.33 million from $209.87 million in the prior-year period, while 13 analysts estimated revenues of $236.95 million.

Further, the company raised its fiscal 2014 earnings to a range of $5.60 to $5.70 per share from its prior range of $5.50 to $5.65 per share. Analysts now expect earnings of $5.62 per share.

The company lowered its full-year revenue guidance to a range of $908 million - $915 million from its previous expectation of $920 million to $940 million. Analysts expect the company to report revenue of $932.04 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT